Skip to main content

The Real India-mHealth & beyond Part 3


Tuberculosis- TB is caused by a bacterium, Mycobacterium tuberculosis, that the WHO says infects one third of the world’s population. Between five and 10 percent of infected people develop the disease and become contagious at some point in their lives. (For those with HIV or AIDS, however, the rate is much higher.)

The Bigger problem- India is the highest TB burden country with World health Organisation (WHO) statistics for 2010 giving an estimated incidence figure of 2.3 million cases of TB for India out of a global incidence of 9.4 million cases. The WHO statistics also show that India is 17th out of the 22 high burden countries in terms of TB incidence rate. The estimated TB prevalence figure for 2010 is given as 3.1 million. It is estimated that about 40% of the Indian population is infected with TB bacteria, the vast majority of whom have latent rather than active TB.
Compliance issues in Treatment- To treat TB, the WHO recommends the so-called DOTS (Directly Observed Treatment Short-course) strategy, where patients take medication under supervision from health staff. Daily supervision of treatment is too demanding for most of our patients and instead implements self-administered therapy with patient education and support to ensure adherence. In many countries affected by conflict, access to health structures is limited for the population. Conflict interrupts travel and makes people fearful of leaving their shelters to seek assistance. It can also lead to the collapse of existing health systems.In India in 2010 292,972 people needed TB re-treatment because of initial treatment relapse, failure or default.

In Focus- Operation ASHA

Operation ASHA is a registered non-profit that has taken TB treatment to the doorsteps of 5.37 million individuals living in disadvantaged areas. It operates in over 2,053 villages and slums in six states spread across India and Cambodia. The effort is self-sustainable and is using technology to reach out to millions everyday.

Establishing Centres- Operation ASHA establishes tuberculosis (TB) treatment centers within existing community locals (for example, strategically placed shops, homes, temples, or health clinics). Under the World Health Organization’s Directly Observed Therapy (DOTS), patients must take their medicines under the supervision of a health care worker. The model is designed to help patients procure their medicines conveniently without wasting time, spending money on transport, and losing wages. This also drastically reduces the effort, time and money that patients have to invest in taking their medication, which is key to ensuring that patients complete the entire course of treatment.

Training- Operation ASHA trains community members (often former patients) to become tuberculosis health workers who are responsible for identifying new patients, ensuring adherence to the drug regimen, and carrying out regular educational campaigns. Operation ASHA works closely with the Government of India, who provides them with free medicines and diagnostic services. After a center has been established for two years, the government provides a grant for every patient cured, making OpASHA’s centers financially self-sustaining.

Building Compliance through technology- Ensuring patient compliance is important because of the threat of multi-drug resistant tuberculosis (MDR-TB), which has become one of the world’s largest public health issues. Resistant strains of the disease can take up to two years to treat (in comparison to the standard 6 month regimen). Second line medicines have more severe side effects and can also cost 50-200 times more. Such unrealistically high costs are essentially a death warrant to those below the poverty line. To combat the rising MDR-TB epidemic, OpASHA launched eCompliance, a biometric initiative in collaboration with Microsoft Research, which uses fingerprint scanners to track patient visits.


The system consists of three parts: 
  • a netbook computer, 
  • a USB fingerprint reader (from Digital Persona), 
  • and a GSM modem that uploads the visitation logs (via SMS) to a central location. 


Patients scan their finger every time they take medication, and these logs are visualized in the central office to monitor medication delivery. Missed doses trigger an SMS notification to managers, who ensure timely supervision or counseling to the patients and health workers involved. The health worker is then required to do a follow-up visit within 48 hours to deliver the medicines and supplementary health education. 

These home visits are also confirmed by biometrics. Currently the terminal is used daily in over 40 treatment centers, spanning Delhi, Mumbai, and Jaitpur; Operation ASHA is aggressively expanding the deployment to over 225 centers around the world. To date, the technology has enrolled about 2,700 patients and logged over 50,000 supervised doses. The biometric records are used to automatically generate reports to the government and other stakeholders.

With the help of eCompliance, Operation ASHA has reduced its default to 1.5%, which is much lower than other institutions. The cost of treating a patient for the entire therapy of is US $50.


References/Credits:

TB statistics of India- TB India 2011 Revised National TB Control Programme Annual Status Report, New Delhi, 2011 www.tbcindia.nic.in/documents.html#

Doctor without borders- http://www.doctorswithoutborders.org/news/issue.cfm?id=2404

Operation ASHA- http://www.opasha.org/



Popular posts from this blog

Artificial Intelligence Policy and Governance in HEALTHCARE

  Artificial Intelligence has become the new frontier for digital transformation. Several  #digitalhealth  businesses of today rely on Machine Learning,  #AI  and other such technologies to make healthcare delivery more efficient and comprehensive. However, the efficient and responsible use of AI tools is an ongoing discussion and would mean culture, data management, technology shifts in the industry, and required up-grading and training professionals for better coordination. Hence, with the growing market potential and interest in AI, it is imperative to develop a thoughtthrough regulatory and legal framework on the adoption and use of AI. I have set forward a hypotheses to design a policy framework for AI technologies in my paper- "𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐏𝐨𝐥𝐢𝐜𝐲 – 𝐀 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞" last year https://lnkd.in/emi3XWwa cited further by "𝐓𝐡𝐞 𝐐𝐮𝐚𝐧𝐝𝐚𝐫𝐲 𝐢𝐧 𝐃𝐚𝐭𝐚 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐑

Artificial intelligence and Technology for Dentistry

Have you heard of this company  ORCA Dental AI ? ORCA combines clinical expertise with machine learning and AI technologies to create diagnostic reports, treatment plan suggestions and smart clinical predictions. Good to learn about these innovations that benefit every stakeholder in the value chain. Recently,  VideaHealth  raised $20M to Expand AI-Based Diagnostics led by Spark Capital including existing investors Zetta Venture Partners. Among its many benefits to dentists and patients are: – A 31% increase in diagnosis rate for cavities and 26% increase in treatment plan value; – An increase in case acceptance by patients due to second opinions; – Automated workflows accelerate treatment planning and charting; Another company touting AI-powered dental care and practice management is  Overjet , which announced a $42.5 million Series B funding round in December months after it had scored $27 million in Series A funding.  Pearl  provides AI for dental images to assist in diagnosis. It l

Big Data Analytics- The Microscope and Telescope for Pharma/CRO

This article is produced in consultation with Industry experts, and KOLs in India and across the world and especially highlights how “Predictive Analytics algorithms” are poised to provide Useful Analytics to the Pharma industry.   In today’s highly competitive market, it is extremely important for contract research and manufacturers to have access to information that allows them to target the specific segments of the pharmaceutical and biotechnology industry that are looking to outsource the particular services they provide.  Understanding shifts in annual outsourcing budgets and spending can help CROs and CMOs to better position themselves for capturing business, particularly at a time when many – if not all – pharma and biotech companies are looking to cut costs and streamline operations.  As per a recent report by NiceInsights, Analytical Services, Clinical Research, and Clinical Monitoring will be the most demanded services over the next 12 to 18 months. For CROs and CMOs looki